Saturday, January 28, 2017 | 11:00 AM - 4:00 PM
This event gives professionals from across the biopharmaceutical space — from scientists and industry executives, through healthcare providers and insurers to investors — a visceral understanding of how biopharma innovation dynamics are evolving, mimicking decision-making under pressure in a complex and changing environment.
February 27 - 28, 2017
Keynote Speaker: James P. Allison (University of Texas MD Anderson Cancer Center)
Discover the latest on immunotherapeutic strategies that are currently being employed to treat some of the most devastating forms of cancer from leading experts in immunotherapy.
This event is sold out.
Monday, March 13, 2017 | 9:00 AM - 5:00 PM
Speakers: Michael G. Agadjanyan (The Institute for Molecular Medicine), Bernardino Ghetti, (Indiana University School of Medicine), Andreas Muhs (AC Immune SA), Michal Novák (AXON Neuroscience SE), Einar M. Sigurdsson (NYU School of Medicine), Henrik Zetterberg (University of Gothenburg, Sweden), and Khalid Iqbal (New York State Institute for Basic Research)
This event will cover the translational potential of immunotherapy for tauopathies, reviewing the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic approach.
March 15 - 16, 2017
Experience a public-facing dialogue exploring the nuanced ethical and scientific rationale behind randomized controlled clinical trials, accelerated alternatives, and the implications of these discussions on drug approval and patient interests.
Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM
Speakers: Brian Kaspar (Nationwide Children's Hospital), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida, Powell Gene Therapy Center), Maria Escolar (Children's Hospital of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and David Pearce (Sanford Research)
Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in the field, and identify ongoing obstacles on the path to wider use of this approach.
Thursday, November 3, 2016 | 9:00 AM - 5:00 PM
Speakers: Henrik Bjørn Nielsen (Clinical-Microbiomics A/S), Martin J. Blaser (New York University Langone Medical Center), Patrice D. Cani (Universite Catholique de Louvain, LDRI), Rachel Carmody (Harvard University), Stanley L. Hazen (Cleveland Clinic), Gerald I. Shulman (Yale University School of Medicine), Marion Soto (Joslin Diabetes Center, Harvard Medical School), and Dan Winer (University of Toronto)
The microbiome is emerging as an important regulator of health, and disease well beyond the digestive tract. This symposium will highlight recent research innovations and therapeutic applications from the microbiome with a focus on metabolic disease.
September 21 - 23, 2016
Featuring: Peder S. Olofsson (Karolinska Institutet) and Kevin J. Tracey (The Feinstein Institute for Medical Research)
Bioelectronic medicine, a new discipline aimed at interfacing electronics with cells to target molecular mechanisms, is at the epicenter of healthcare, technology, and science. This symposium will advance the technological promise of bioelectronics.
Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM
Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)
Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.
Wednesday, May 25, 2016 | 11:30 AM - 5:00 PM
Speakers: Philip A. Cole (Johns Hopkins University School of Medicine), Kenneth W. Duncan (Epizyme, Inc.)
The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs. In 2016, the annual year-end meeting features keynote speakers Dr Philip Cole and Dr Kenneth Duncan.
Keynote Speakers: Barry G. Arnason, MD (University of Chicago) and Giancarlo Comi, MD (Università Vita-Salute San Raffaele)
This one-day, translational conference brought together academic and clinical researchers with industry leaders to discuss current therapeutics.
Edited by Annals of the New York Academy of Sciences
This special issue presents a collection of four papers ranging from proapoptotic and antiangiogentic properties of resveratrol, to executive function of in adults with beta-thalassemia, to disease drivers of aging.
Keynote Speakers: The Honorable Patrick J. Kennedy (Former United States Representative, Rhode Island; Co-Founder, One Mind; and Founder, Kennedy Forum), George F. Koob (National Institute on Alcohol Abuse and Alcoholism, U.S. National Institutes of Health), and Nora D. Volkow (National Institute on Drug Abuse, U.S. National Institutes of Health)
Leading experts, including NIAAA and NIDA directors, discuss the latest on neurobiology of addiction; susceptibility of the teen brain; new treatment strategies; and social, economic, political, and legislative aspects of this disease.
Edited by Annals of the New York Academy of Sciences
This diverse collection of papers discusses topics ranging from a paleobiologic study of the emergence of the diaphragm to changes in gait patterns after acute brain injury.